SNBP - Sun BioPharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
4.5000
0.0000 (0.00%)
At close: 2:27PM EST
Stock chart is not supported by your current browser
Previous Close4.5000
Open4.5000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.5000 - 4.5000
52 Week Range2.0000 - 7.0000
Volume100
Avg. Volume198
Market Cap29.841M
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-1.1240
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium

    Sun BioPharma, Inc. (SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, today summarized initial Phase 1  clinical data for SBP-101, which was presented in a poster session at the American Society for Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium. SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in cell function in multiple tumor types. Based upon the study data presented today, the adverse event profile of SBP-101 at the optimal dose level was manageable and an expansion study in patients with pancreatic ductal adenocarcinoma (PDA) is planned to begin during the second quarter of 2020.

  • GlobeNewswire

    Sun BioPharma, Inc. Announces Data Presentation at the ASCO 2020 Annual Gastrointestinal Cancers Symposium

    Sun BioPharma, Inc. (SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, today announced that an abstract describing Phase 1 clinical data for SBP-101 has been accepted for poster presentation January 24, 2020 at the American Society for Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium, being held January 23-25 in San Francisco. SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) a metabolic pathway of critical importance in multiple tumor types. Sun BioPharma also announced that Arthur J. Fratamico, RPh, MBA recently joined its Board of Directors.

  • GlobeNewswire

    Sun BioPharma, Inc. Provides a Business Update and Reports Q3 2019 Financial Results

    Enrollment in Third Cohort of the PDA Combination Study completed; Fourth Cohort plannedNew U.S. sites added in anticipation of further clinical developmentCompany raised $3.1.

  • GlobeNewswire

    Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2019

    Enrollment in Third Cohort of PDA Combination Study is Encouraging                              Preliminary Efficacy Signals Improve with New Data Regarding Second CohortEntire.

  • GlobeNewswire

    Sun BioPharma, Inc. Provides an Update on Ongoing Front-line Pancreatic Cancer Clinical Trial

    Sun BioPharma, Inc. (SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides an update on the Company’s current clinical trial. Following successful conclusion of the first SBP-101 dose escalation study in heavily pretreated pancreatic cancer patients that showed SBP-101 could be administered safely as monotherapy, a second Phase 1 safety study entitled, “SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxel in Newly Diagnosed Patients with Metastatic Pancreatic Ductal Adenocarcinoma” was undertaken to evaluate the addition of SBP-101 to front line gemcitabine and nab-paclitaxel treatment.

  • GlobeNewswire

    Sun BioPharma, Inc. Provides a Business Update and Files Report for Q1 2019

    Enrollment in Second Cohort of PDA Combination Study CompletedNew Funding Totaling $0.8 Million Secured MINNEAPOLIS, May 14, 2019 -- Sun BioPharma, Inc. (OTCQB:SNBP), a.

  • GlobeNewswire

    Sun BioPharma Provides Business Update and Files Annual Report for 2018

    Front-Line Combination Study with Gemcitabine and Nab-Paclitaxel enrolling second Cohort of Phase 1a Company reinstates founder and Executive Chairman, Dr. Michael Cullen as.